ライフサイエンスコーパス: inhaler

1 red adherence (number of doses left in study inhalers).

2 ts (81%) reported benefit from the albuterol inhaler.

3 lung after administration from the Azmacort inhaler.

4 ly for 52 weeks via pressurised metered-dose inhaler.

5 n treatment to triple therapy using a single inhaler.

6 th different mechanism of action in a single inhaler.

7 who overrely on their reliever beta-agonist inhaler.

8 ts were delivered via the ELLIPTA dry powder inhaler.

9 inistered through a pressurized metered-dose inhaler.

10 er inhalers (DPI's) varies with the specific inhaler.

11 on plan and coaching in proper use of asthma inhalers.

12 y pulmonary deposition patterns from aerosol inhalers.

13 ticosteroids and 2 or fewer dispensed rescue inhalers.

14 e the delivery to the airways via dry powder inhalers.

15 e level of commercially available dry powder inhalers.

16 e in the mean FEV(1 )while using the placebo inhaler (1.70 L versus 1.60 L, baseline versus placebo:

17 ctively; P=0.50), use of an albuterol rescue inhaler (2.8 and 3.0 inhalations per week, respectively;

18 Patients received IB by metered-dose inhaler (40mug per dose) with a spacer three times at 20

19 albuterol inhaler (50% improvement), placebo inhaler (45%), or sham acupuncture (46%), but the subjec

20 d not differ significantly for the albuterol inhaler (50% improvement), placebo inhaler (45%), or sha

21 asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no inte

22 safety of combination budesonide/formoterol inhaler according to a single inhaler regimen (SMART) wi

23 her doses, differing potency claims, and new inhalers also affect the potential for systemic effects

24 cerbations (daily symptoms and use of rescue inhalers) among 990 children in eight North American cit

25 ing 12 months, 207 (53%) started their study inhaler and 46 (12%) started prednisolone--22 (11%) of 1

26 TIO was delivered via the HandiHaler inhaler and all other active treatments were delivered v

27 combination of nicotine patch, nicotine oral inhaler, and bupropion ad libitum (n = 63).

28 le, including nicotine nasal spray, nicotine inhaler, and bupropion hydrochloride.

29 control medications, overuse of quick-relief inhalers, and a significant number of self-reported asth

30 for the development of a medical cannabinoid inhaler; and recommends that compassionate use of mariju

31 Breath-actuated inhalers are easier to use than pMDIs.

32 beta-agonist or ICS/long-acting beta-agonist inhaler as a reliever rather than regular maintenance us

33 ercise was increased while using the placebo inhaler as compared with baseline, and decreased during

34 eta-agonist (SABA) delivered by metered-dose inhaler as first-line therapy for younger and older chil

35 chewing gum, skin patches, nasal sprays, and inhalers, as well as pharmacotherapies such as mecamylam

36 Ten metered-dose inhaler canisters were used to administer 2000 microgram

37 risk that the lactose-containing dry powder inhalers cause allergic reactions for patients with cow'

38 The rationale behind inhaler choice should be evidence based rather than empi

39 gned this study to assess efficacy of single-inhaler combination of an extra fine formulation of becl

40 eling and the prescription of a metered-dose inhaler containing either ipratropium bromide or placebo

41 In addition, the use of a single inhaler containing ICS and a quick-acting beta2AR agonis

42 We conclude that Spiros and Ventolin inhalers deliver comparable quantities of albuterol to t

43 Dosage, type of inhaler device used, patient technique, and characterist

44 When choosing an inhaler device, it is essential that it is easy to use c

45 ide variety of reasons, but incorrect use of inhaler devices is amongst the most common.

46 systemic corticosteroid and 3 or less rescue inhalers dispensed in periods 2 and 3.

47 uggested that we should instruct patients to inhaler DPI based on inspiratory resistance of the DPI.

48 Flow resistance of dry powder inhaler (DPI) is important information when physician ch

49 ative delivery system, the Spiros dry-powder inhaler (DPI), with Ventolin, using a methacholine chall

50 e optimal inhalation effort using dry powder inhalers (DPI's) varies with the specific inhaler.

51 Because dry powder inhalers (DPI) aerosolize agents by means of inspiration

52 or flow instruction in the use of dry powder inhalers (DPI).

53 orofluorocarbon [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered

54 f micro/nano-particles, transdermal patches, inhalers, drug reservoir implants and antibody-drug conj

55 s: inhaler therapy at entry; commencement of inhalers during follow-up; death from respiratory causes

56 dred twenty-one subjects used a quick-relief inhaler for asthma symptoms, and 14.6% used more than 3

57 Short-acting inhalers for "rescue therapy" were not evaluated.

58 m the corresponding pressurized metered-dose inhaler formulations (pMDIs) that have excellent aerosol

59 a history of wheezing or use of respiratory inhalers in the last 12 months.

60 ronchodilator administration by metered-dose inhaler is becoming the preferred therapy for treating m

61 clinicians in understanding why a prescribed inhaler is not effective and to devise strategies to pro

62 The Single combination budesonide-formoterol inhaler Maintenance And Reliever Therapy (SMART) regimen

63 (15-microg dose) and 200 microg metered-dose inhaler (MDI) albuterol.

64 orofluorocarbon (CFC)-propelled metered-dose inhaler (MDI) during mechanical ventilation, obtained by

65 l bronchodilator therapy with a metered-dose inhaler (MDI) in intubated, mechanically ventilated pati

66 haling racemic albuterol with a metered-dose inhaler (MDI) is not known.

67 medication knowledge and worse metered-dose inhaler (MDI) technique, the relationship between health

68 of aerosol administration by a metered-dose inhaler (MDI), we measured serum albuterol levels after

69 delivered through a combination metered dose inhaler (MDI), with one extra actuation as needed for re

70 ess the use of beta-agonists by metered dose inhaler (MDI).

71 luticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-CFC, and triamcinolone-CFC),

72 ures on albuterol delivery from metered-dose inhalers (MDIs) and jet nebulizers in an in vitro model

73 In nonintubated patients, metered-dose inhalers (MDIs) are accepted as the most convenient, eff

74 tospheric ozone, CFC-containing metered-dose inhalers (MDIs) such as Ventolin and Proventil are being

75 ns, quality of life, and use of metered dose inhalers (MDIs), may be related to this difference in re

76 tion of 180 microg albuterol by metered dose inhaler, mean Qaw increased by 83 +/- 26% in normal subj

77 Inhaler monitors recorded fluticasone propionate/salmete

78 defined as poor adherence to ICS or ICS/LABA inhaler of 75% or less.

79 nhalation per day via single-dose dry-powder inhaler of open-label 18 mug tiotropium, patients were r

80 g) or placebo, both delivered by a soft-mist inhaler once daily for 48 weeks.

81 with a shorter-acting product (lozenge, gum, inhaler, or nasal spray) and extend treatment beyond 12

82 ntaneous nebulizers (p = .001), metered dose inhalers (p = .01), and pulse oximetry (p = .02).

83 The pressurised metered-dose inhaler (pMDI) is still the most frequently used device

84 desonide/formoterol pressurized metered-dose inhaler (pMDI) versus budesonide over 1 year in African

85 ck test showed positive reactions for Inavir inhaler powder and lactose used as an excipient but nega

86 The lactose excipient in Inavir inhaler powder was supposed to contain milk proteins, wh

87 ed HR, 1.22 [95% CI, 1.11-1.34]), salbutamol inhaler prescription at age 5 years (10.34% vs 9.62%; di

88 hma requiring hospital admission, salbutamol inhaler prescription at age 5 years, and all-cause death

89 dmission; secondary outcomes were salbutamol inhaler prescription at age 5 years, obesity at age 5 ye

90 hma requiring hospital admission, salbutamol inhaler prescription at age 5 years, obesity at age 5 ye

91 ating different combination ICS/beta-agonist inhaler products prescribed according to this regimen in

92 ilarity of in vivo performance of dry powder inhaler products.

93 k or directly intranasal with two dry powder inhalers, PuffHaler and BD Solovent.

94 ide/formoterol inhaler according to a single inhaler regimen (SMART) with a fixed-dose regimen with s

95 ial, with GP as unit of cluster, we compared inhaler reminders and feedback (IRF) and/or personalized

96 Inhaler reminders offer an effective strategy for improv

97 Feasibility of deploying inhaler sensors to identify the impacts of environmental

98 We found that the inhaler sensors were feasible in passively collecting ob

99 eatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention.

100 livered at a dose of 5 mug with the Respimat inhaler showed efficacy similar to that of 18 mug of tio

101 ion), five denied nonadherence, two had poor inhaler technique (unintentional nonadherence), and one

102 ment plan (SMP) [0.554 (0.515; 0.593)], poor inhaler technique [0.53 (0.475; 0.585)], poor medication

103 navigational ability are likely to have poor inhaler technique and limited understanding of ICS funct

104 Inhaler technique improved substantially in both groups.

105 care alone; all GPs received action plan and inhaler technique training.

106 asic management needs, such as adherence and inhaler technique, are corrected) or true, therapy-resis

107 ristics (including self-management plan use, inhaler technique, medication compliance) appear to be t

108 brief introduction of aerosol properties and inhaler technology is followed by considerations of in v

109 aily, the challenge is to develop a combined inhaler that can be employed on a daily basis.

110 this might be addressed by using combination inhalers that contain a corticosteroid and long-acting b

111 r IgA titer and any of the outcome measures: inhaler therapy at entry; commencement of inhalers durin

112 ively quantify adherence to preventer Diskus inhaler therapy by patients with COPD with an electronic

113 sis of symptomatic asthma and on maintenance inhaler therapy were randomly assigned to initiate treat

114 y treated with triple fixed-dose combination inhaler therapy with an inhaled corticosteroid, long-act

115 sis of symptomatic asthma and on maintenance inhaler therapy, initiation of a once-daily treatment re

116 ts added an active or placebo corticosteroid inhaler to their usual corticosteroid for 14 days to pro

117 Electronic sensors fitted on metered dose inhalers tracked 5,660 rescue inhaler use events in spac

118 These results support the benefits of single-inhaler triple therapy compared with ICS/LABA therapy in

119 to 180 mug or 200 mug budesonide dry powder inhaler twice daily for the entire duration of the study

120 tion and ED visits, six or more beta-agonist inhalers (units) during the prior 6 mo, and three or mor

121 increased by 0.1 to 0.3/1,000 spores/m3) and inhaler use (0.1 to 0.4 puffs/1,000 spores/m3) across sp

122 but not 1-h maximum O3, was associated with inhaler use (p < 0.03).

123 Cluster 1 (34%) had low inhaler use and high error rates.

124 Cluster 2 (25%) had high inhaler use and high error rates.

125 Concomitant rescue beta-agonist inhaler use and the need for corticosteroid rescue are a

126 t environment factors associated with rescue inhaler use and to determine whether these findings woul

127 (-0.42% [CI, -3.74% to 2.91%]), symptoms, or inhaler use compared with placebo but maintained an 8.74

128 to test the feasibility of collecting rescue inhaler use data in space-time using electronic sensors.

129 ble in passively collecting objective rescue inhaler use data.

130 oms (functional levels 0 to 5) and as-needed inhaler use during September and October 1993 in San Die

131 n metered dose inhalers tracked 5,660 rescue inhaler use events in space and time for 140 participant

132 ing a sensor to capture the signal of rescue inhaler use in space-time offered a passive and objectiv

133 ores increased by 25% (95% CI: 0 to 49%) and inhaler use increased by 26% (95% CI: 3 to 48%) over the

134 espectively, and with rate ratios for rescue inhaler use of 1.06 (95% CI: 1.01, 1.10) and 1.05 (95% C

135 models to identify triggers associated with inhaler use, and implemented three sensitivity analyses

136 KL-40 had significantly more frequent rescue-inhaler use, greater oral corticosteroid use, and a grea

137 a positive and significant association with inhaler use, including: AQI, PM10, weed pollen, and mold

138 a negative and significant association with inhaler use.

139 quantified the frequency and proficiency of inhaler use.

140 th a short-acting beta-agonist as a separate inhaler used when needed for symptom relief.

141 and combination NRT (31.5%) (eg, patch plus inhaler) were most effective for achieving smoking cessa

142 ill required significant use of quick-relief inhalers, whereas 28% had never used long-term control m

143 Conventional coarse-particle inhalers, which emit particles larger than 2 mum, might

144 tecting the dose delivered from a dry powder inhaler while sampling for aerodynamic particle size dis

145 given liquid dextromethorphan and albuterol inhaler with a spacer.

146 28) or placebo (n = 13) using a metered-dose inhaler with a spacer.

147 patients were given a salmeterol/fluticasone inhaler with an INCA device attached.

148 We aimed to investigate whether use of an inhaler with audiovisual reminders leads to improved adh

149 nitoring device for use with their preventer inhaler with the audiovisual reminder functions either e

150 /vilanterol 100 mug/62.5 mug/25 mug; ELLIPTA inhaler) with twice-daily ICS/LABA therapy (budesonide/f

151 ination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone

152 d patients prescribed combination controller inhalers, with suboptimal Asthma Control Test (ACT) scor